PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

doi:10.1126/scitranslmed.aaa4442

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Science translational medicine - 15 Apr 2015

Bosch Ana, Li Zhiqiang, Bergamaschi Anna, Ellis Haley, Toska Eneda, Prat Aleix, Tao Jessica J, Spratt Daniel E, Viola-Villegas Nerissa T, Castel Pau, Minuesa Gerard, Morse Natasha, Rodón Jordi, Ibrahim Yasir, Cortes Javier, Perez-Garcia Jose, Galvan Patricia, Grueso Judit, Guzman Marta, Katzenellenbogen John A, Kharas Michael, Lewis Jason S, Dickler Maura, Serra Violeta, Rosen Neal, Chandarlapaty Sarat, Scaltriti Maurizio, Baselga José

Abstract excerpt

Activating mutations of PIK3CA are the most frequent genomic alterations in estrogen receptor (ER)-positive breast tumors, and selective phosphatidylinositol 3-kinase α (PI3Kα) inhibitors are in clinical development. The activity of these agents, however, is not homogeneous, and only a fraction of patients bearing PIK3CA-mutant ER-positive tumors benefit from single-agent administration. Searching for mechanisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endoplasmic Reticulum

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to MCF-7 Cells

Share to Mice, Nude

Share to Neoplasm Transplantation

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Research Design

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 25877889
DOI: 10.1126/scitranslmed.aaa4442
PMCID: PMC4433148

Genes

ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.PMID 25877889Read ↗

Overview of the relevance of PI3K pathway in HR-positive breast cancerSemantic proximity Read ↗

Nexus Between PI3K/AKT and Estrogen Receptor Signaling in Breast CancerSemantic proximity Read ↗

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.Semantic proximity Read ↗

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Semantic proximity Read ↗

ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast CancerSemantic proximity Read ↗

Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast CancerSemantic proximity Read ↗

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.Semantic proximity Read ↗

A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genesSemantic proximity Read ↗

Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.Semantic proximity Read ↗

Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.Semantic proximity Read ↗

ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.